trending Market Intelligence /marketintelligence/en/news-insights/trending/oqKkypEhTkCKkx5Arco6kA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Cardax plans 200-for-1 reverse stock split

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Cardax plans 200-for-1 reverse stock split

Cardax Inc. said it will effect a 200-for-1 reverse split of its issued and outstanding common stock.

The Honolulu-based biopharmaceutical company said the reverse stock split will be effective at 12:01 a.m. ET on Jan. 15.

The company's common stock will trade on the OTCQB on a split-adjusted basis under its current CDXI ticker symbol.

No fractional shares will be issued under the stock split. Fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share.

Cardax develops dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress.